This 2019 document presents a limited update of the 2018 version.
Summary of changes
New relevant references have been identified through a structured assessment of the literature and incorporated in the various chapters of the 2019 EAU MIBC Guidelines.
Key changes in the 2019 print are:
- Section 6.3 Prognostic markers – this section was revised, to include new data. Based on the current data, no recommendation can be provided.
- Figures 7.1: Flow chart for the management of T2-T4a N0M0 urothelial BC was adapted.
- Section 7.2 Neoadjuvant therapy – this section was revised and restructured. A new recommendation was added.
- New Section 7.4.7 – Impact of hospital and surgeon volume on treatment outcomes, has been included. This section is based on the findings of a systematic review (SR) on ‘The impact of the annual hospital and surgeon radical cystectomy volume for BC on peri-operative outcomes and long-term oncological outcomes’ [5];
- Section 7.6.2 External beam radiotherapy (EBRT) – this section was revised, to include new data. The recommendations did not change.
- Section 7.6.4 Multimodality bladder-preserving treatment – this section was revised, to include new data. The recommendations did not change.
- Section 7.7 Adjuvant therapy – this section was revised, to include new data. A new recommendation was included.
- Section 7.8 Metastatic disease – this section was revised, to include new data, resulting in changes to both the Summary of evidence and the recommendations.
- Figure 7.2: Flow chart for the management of metastatic urothelial cancer was adapted.
- Section 7.9 Quality of life – this section was revised to include new data. However, the recommendations did not change.
For more details, please see the EAU MIBC Guidelines here.